CBLL

ANALYST NOTE: CeriBell, Inc. (CBLL) Date: 2026-06-20 Event Date: 2026-06-20

1. Structural Readiness

As of the close on 2026-06-20, CeriBell, Inc. presents a confirmed coil setup. The structure has fired a breakout signal, placing the stock in the "watchlist" state with positive readiness.

• Conservative Entry: $24.40
• Current Price: $24.21
• Extension: -0.8% vs. conservative entry
• Setup Status: The setup is confirmed. The stock is currently trading slightly below the conservative entry level, indicating a minor pullback or consolidation within the breakout structure rather than a failure of the setup.
• Volatility Context: The ATR at breakout was recorded at 4.2% (High), and the current ATR remains at 4.2% (High). This places the stock in the historical "sweet spot" for structural quality, suggesting sufficient volatility to support a move without the extreme risk associated with >8% ATR readings.

2. The Thesis Layer

At this date, CeriBell is classified as a TACTICAL, setup-led name. There is no named secular thesis attached to this specific setup in the current evidence base. The conviction for this position must be derived strictly from the quality of the technical structure (the confirmed coil) and the immediate business fundamentals reported in the most recent filings, rather than a broader macro or thematic narrative.

3. The Business

CeriBell, Inc. is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company operates in the Healthcare sector, specifically within the acute care monitoring space.

Business Model: The company generates revenue through two recurring sources:

• Sale of Wearables: Single-patient use devices.
• Subscription Fees: Monthly recurring revenue charged to hospital customers for the use of the Clarity software, recorders, and the cloud-based portal.

Operational Evidence (as of 2026-06-20):

• Revenue Growth: In the quarter ended March 31, 2026 (reported May 11, 2026), the company delivered revenue of $26.5 million, representing 29% year-over-year growth and 7% sequential growth.
• Guidance: Management expects full-year 2026 total revenue to range from $112 million to $116 million, an upward revision from the prior guidance of $111 million to $115 million.
• Customer Base: As of Q1 2026, the Ceribell System was actively used by 680 hospitals, marking the strongest single quarter of account growth since becoming a public company with 33 net additions.
• Product Pipeline & Regulatory:
• Delirium Solution: The company is on track for a full commercial launch of its delirium solution in Q4 2026 or Q1 2027.
• Reimbursement: In April 2026, the company received a supportive CMS proposed rule for a New Technology Add-on Payment (NTAP) for the delirium monitoring solution, proposing up to $2,171 in incremental reimbursement per patient.
• FDA Clearances: The company received FDA 510(k) clearance for its proprietary delirium monitoring solution in December 2025 and FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection solution in January 2026.
• Financial Health: Based on the operating plan as of May 2026, the company believes its existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures for at least the next 12 months.
• Profitability: For the year ended December 31, 2025, the company recognized a gross margin of 88% but reported a net loss of $53.4 million, compared to a net loss of $40.5 million in 2024. Management expects to incur losses in the near term as it expands corporate infrastructure and promotes new products.

4. Archetype and Conviction

Archetype: Growth Leader / Margin Inflector CeriBell fits the archetype of a commercial-stage growth leader with a high-margin business model (88% gross margin) that is currently inflecting toward scale. The company is transitioning from a pure R&D phase to a commercial expansion phase, evidenced by the rapid hospital adoption (680+ sites) and the imminent commercial launch of the delirium solution.

Conviction Stack:

• Thesis Strength: Moderate. While there is no named secular thesis, the business fundamentals are robust, showing accelerating revenue and expanding TAM (Total Addressable Market estimated at $3.5 billion in the U.S.).
• Evidence Quality: High. The evidence base is rich with primary source data from earnings transcripts and SEC filings, providing clear visibility into revenue, guidance, and regulatory milestones.
• Structural Quality: High. The ATR of 4.2% (High) indicates a healthy, active stock with the volatility necessary for a breakout, without the extreme risk of "extreme" volatility buckets.
• Rerating Potential: Significant. The combination of raised full-year guidance, strong hospital adoption, and the potential for NTAP reimbursement creates a catalyst for multiple expansion as the market recognizes the commercial viability of the delirium platform.

5. Invalidation, Strengthening, and Gaps

What Would Strengthen the Case:

• Confirmation of the NTAP reimbursement rule finalization and actual billing data from the first commercial delirium deployments.
• Continued sequential revenue growth exceeding the 7% Q1 pace in Q2.
• Further expansion of the hospital base beyond the 680 reported in Q1.

What Would Invalidate the Case:

• A failure to launch the delirium solution by the stated Q4 2026 / Q1 2027 window.
• A significant slowdown in hospital account additions or a reversal in the 33 net additions trend.
• A breach of the cash runway, requiring dilutive financing before the 12-month horizon.

Gaps in the Evidence Base:

• Q2 2026 Financials: As of 2026-06-20, the Q2 2026 earnings report (scheduled for August 10, 2026) has not yet been released. Therefore, specific Q2 revenue figures, updated loss per share, and updated cash balances are missing from the current evidence set.
• Delirium Commercial Data: While the launch is expected in Q4/Q1, there is no historical revenue data from the delirium product line yet, as it is not yet commercially launched.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Confirmed coil setup with high structural ATR; raised full-year 2026 revenue guidance to $112-116M; 680 active hospitals with 33 net additions in Q1 2026. Key risks: Company remains unprofitable with widening net losses; Q2 2026 financial results not yet reported; commercial launch of delirium solution delayed beyond Q1 2027. Rating boundary: This is rated Buy rather than Strong Buy because the current price is trading below the conservative entry level, indicating the setup has not yet fully re-established momentum, and the Q2 earnings data is missing. It is rated above Speculative due to the confirmed breakout structure and the high quality of the business fundamentals (88% gross margin, strong growth). Sizing hint: Position size should reflect the high ATR volatility and the slight pullback from entry; standard sizing for a confirmed coil with high volatility is appropriate. Expected path: Management expects revenue to accelerate as the delirium solution launches and NTAP reimbursement takes effect, driving further hospital adoption and revenue growth through 2027. Expected horizon: 6 to 12 months, aligning with the commercial launch window and the 12-month cash runway. Failure mode to watch: A significant miss in Q2 2026 revenue or a delay in the delirium commercial launch that pushes the timeline beyond Q1 2027.